KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Assets Average (2019 - 2026)

Castle Biosciences' Assets Average history spans 7 years, with the latest figure at $570.7 million for Q4 2025.

  • On a quarterly basis, Assets Average rose 9.14% to $570.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $570.7 million, a 9.14% increase, with the full-year FY2025 number at $554.9 million, up 12.72% from a year prior.
  • Assets Average hit $570.7 million in Q4 2025 for Castle Biosciences, up from $553.8 million in the prior quarter.
  • Over the last five years, Assets Average for CSTL hit a ceiling of $570.7 million in Q4 2025 and a floor of $426.1 million in Q2 2023.
  • Historically, Assets Average has averaged $471.4 million across 5 years, with a median of $453.0 million in 2022.
  • Biggest five-year swings in Assets Average: soared 265.27% in 2021 and later dropped 5.98% in 2023.
  • Tracing CSTL's Assets Average over 5 years: stood at $448.1 million in 2021, then increased by 0.99% to $452.6 million in 2022, then dropped by 1.74% to $444.7 million in 2023, then rose by 17.59% to $522.9 million in 2024, then increased by 9.14% to $570.7 million in 2025.
  • Business Quant data shows Assets Average for CSTL at $570.7 million in Q4 2025, $553.8 million in Q3 2025, and $523.2 million in Q2 2025.